drugset / Trial / NCT03761914
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Phase 1/2
Completed
26 enrolled
Sellas Life Sciences Group
LumaBridge · collabMerck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
Timeline
- Start
- 2019-09-30
- Primary completion
- 2022-07-05
- Completion
- 2022-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galinpepimut-S | Vaccine | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | sargramostim | Protein / enzyme biologic | 70 ug | Subcutaneous |